Comparison of 18F-DOPA versus 68Ga-DOTA-TOC as preferred PET imaging tracer in well-differentiated neuroendocrine neoplasms

#3103

Introduction: 18F-DOPA and 68Ga-DOTA-TOC are two diagnostic PET tracers used in neuroendocrine neoplasms (NENs). As both tracers utilise different metabolic pathways, lesion detection results often show disparities, but comparative studies are lacking.

Aim(s): To retrospectively compare both tracers in lesion detection rate and laboratory tumor markers, in patients with NENs.

Materials and methods: All patients with histologically proven NEN between May 2015 and February 2019 were included, who underwent both 18F-DOPA and 68Ga-DOTA-TOC PET within six months from each other. All patients, except those with pancreatic NEN, received carbidopa before 18F-DOPA PET. Based on the number of lesions found by both tracers, patients were divided into three groups: DOPA>DOTA, DOTA>DOPA, and DOPA=DOTA. Chromogranin A, serotonin, and 5-HIAA were retrieved from the patients’ charts.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Veenstra E

Authors: Veenstra E, de Groot D, Brouwers A, Walenkamp A, Noordzij W,

Keywords: neuroendocrine tumor, PET, tracer, 18F-DOPA, 68GA-DOTA-TOC, tumor marker, carbidopa,